A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TRK-750 in Colorectal Cancer Patients With Chemotherapy-induced Peripheral Neuropathy Following Oxaliplatin-containing Chemotherapy in the Adjuvant Setting
Latest Information Update: 12 Sep 2023
At a glance
- Drugs TRK 750 (Primary)
- Indications Chemotherapy-induced damage; Peripheral neuropathies
- Focus Adverse reactions
Most Recent Events
- 03 Mar 2022 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 27 Feb 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 17 Feb 2022 This trial has been discontinued in Denmark and Spain, according to European Clinical Trials Database record.